Evidence map›Paper›PMID 38595818›Full record

SynthesisFrontiers in oncology2024

Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis.

Jingkui Zhu, Jixin Fan, Tiantian Xie, Haiqiu Zhao, Runqing Lu, Yinyin Zhang, Yingmei Li, Xinsheng Xie, Dingming Wan, Zhongxing Jiang and 2 more

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Jingkui Zhu *Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jixin Fan *Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tiantian Xie *Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Haiqiu ZhaoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Runqing LuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yinyin ZhangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yingmei LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xinsheng XieDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dingming WanDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhongxing JiangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Fei HeDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Rong GuoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To compare the efficacy and safety of venetoclax (VEN) in combination with chemotherapy (chemo) versus chemo alone in the treatment of acute myeloid leukemia (AML). Method: To compare the efficacy and/or safety of VEN+chemo versus chemotherapy alone for AML, PubMed, Embase, Web of Science, and the Cochrane Library were used to searching up to June 2023. Comparisons included complete remission (CR), CR with incomplete hematologic recovery (CRi), morphologic leukemia-free state (MLFS), overall response rate (ORR), and adverse events (AEs). Result: A total of 9 articles were included, including 3124 patients. The baseline characteristics between two patient groups were similar. The combined analysis showed that compared with the group receiving chemo alone, the VEN+chemo group exhibited higher rates of CR, CRi, MLFS and ORR. Additionally, the VEN+chemo group had longer event-free survival (EFS) and overall survival (OS) durations. The incidence rates of AEs and serious AEs (SAEs) were similar between the two groups, but the early 30-day mortality rate was lower in the VEN+chemo group than in the chemo alone group. Conclusion: The VEN+chemo therapy demonstrates significant efficacy and safety profile in AML patients. However, more prospective studies are needed in the future to provide more accurate and robust evidence for treatment selection in patients. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023439288, identifier CRD42023439288.

Indexed as

acute myeloid leukemiaadverse eventschemotherapy, efficacymeta-analysisvenetoclax

Identifiers

PMID38595818
PMCPMC11002170
OpenAlexW4393197307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.